FDA Updates Atripla Labeling

“FDA recently approved updates to the Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablet label to include the following changes: Lists Stribild as one of the drugs that should not be coadministered with Atripla Adds drug interaction information for raltegravir, boceprevir and telaprevir Strengthens Warnings and Precautions: Rash section Updates the Use in Specific Populations: Nursing Mothers section Updates Tables 7 and 8 with didanosine drug interaction data based upon recent changes to the prescribing information for Sustiva, Truvada and Viread.” The updated labeling will be available at the FDA website. More information is available: FDA: Press release AIDSinfo: Atripla patient drug summary